Zoetis (ZTS)
(Delayed Data from NYSE)
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Zacks News
Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.
The Zacks Analyst Blog Highlights: General Motors Co., Tesla Inc., Marvell Technology Inc., FedEx Corp. and Zoetis Inc
by Zacks Equity Research
General Motors Co., Tesla Inc., Marvell Technology Inc., FedEx Corp. and Zoetis Inc are highlighted in this Analyst Blog article.
Top 5 Stocks to Buy on the Dip Despite Market Fluctuations
by Nalak Das
We have narrowed our search to five U.S. corporate giants (market capital > $50 billion) that are currently trading on the dip. These are: TSLA, GM, FDX, MRVL and ZTS.
Here's Why Seasoned Investors are Retaining Mednax (MD)
by Zacks Equity Research
Banking on its strategic measures and a streamlined business, Mednax (MD) holds potential to reap benefits for investors.
Why Holding Anthem (ANTM) in Your Portfolio is a Prudent Move?
by Zacks Equity Research
Riding high on its strategic measures and a rising membership, Anthem (ANTM) holds prospects to reap benefits for investors.
Here's Why Zoetis (ZTS) is Poised for a Turnaround After Losing 8.8% in 4 Weeks
by Zacks Equity Research
Zoetis (ZTS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CORT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
CORT vs. ZTS: Which Stock Is the Better Value Option?
JAZZ's Xywav Gets Orphan Drug Exclusivity for Hypersomnia
by Zacks Equity Research
The FDA bestows an Orphan Drug Exclusivity to Jazz's (JAZZ) Xywav for treating idiopathic hypersomnia in adults. This is the second Orphan Drug Exclusivity for the drug.
Acadia Healthcare (ACHC) Buys Real Estate to Expand in Chicago
by Zacks Equity Research
Acadia Healthcare (ACHC) purchases real estate in Illinois to serve the local communities with better healthcare facilities.
Ensign Group (ENSG) Hikes Dividend to Share More Profits
by Zacks Equity Research
Ensign Group's (ENSG) dividend hike reflects its intention to enhance shareholders' value supported by its strong financial position.
The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab
Top Stock Reports for Walmart, Honeywell & Zoetis
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Honeywell International Inc. (HON), and Zoetis Inc. (ZTS).
Zoetis' (ZTS) Earnings and Revenues Surpass Estimates in Q3
by Kanishka Das
Zoetis' (ZTS) earnings and revenues beat estimates in the third quarter of 2021. The company raised its financial guidance for 2021.
Zoetis (ZTS) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 13.64% and 2.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.
Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q3 earnings might have gained from the solid performance of Viagra, Dymista, and the Thrombosis portfolio.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenues, and provide updates on its diversified product portfolio when it releases third-quarter 2021 results.
Humana (HUM) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) third-quarter earnings are expected to have gained from higher revenues and a solid contribution from its Retail and Healthcare Services segments.
4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Zoetis (ZTS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH